Viking Therapeutics (NASDAQ:VKTX) Stock Price Up 0.1%

Viking Therapeutics, Inc. (NASDAQ:VKTXGet Free Report)’s share price shot up 0.1% during mid-day trading on Friday . The stock traded as high as $72.40 and last traded at $70.66. 553,291 shares traded hands during trading, a decline of 91% from the average session volume of 6,411,522 shares. The stock had previously closed at $70.59.

Wall Street Analyst Weigh In

Several brokerages have issued reports on VKTX. Raymond James lifted their target price on shares of Viking Therapeutics from $37.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. William Blair reiterated an “outperform” rating on shares of Viking Therapeutics in a research report on Friday, February 23rd. HC Wainwright reiterated a “buy” rating and set a $90.00 target price on shares of Viking Therapeutics in a research report on Friday, March 15th. Oppenheimer lifted their target price on shares of Viking Therapeutics from $46.00 to $116.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th. Finally, Jefferies Financial Group began coverage on shares of Viking Therapeutics in a research report on Thursday, March 7th. They set a “buy” rating and a $110.00 target price for the company. One analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, Viking Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $96.67.

Get Our Latest Analysis on VKTX

Viking Therapeutics Price Performance

The stock has a market capitalization of $6.99 billion, a PE ratio of -75.60 and a beta of 1.06. The firm’s 50 day simple moving average is $45.58 and its 200 day simple moving average is $25.00.

Viking Therapeutics (NASDAQ:VKTXGet Free Report) last issued its earnings results on Wednesday, February 7th. The biotechnology company reported ($0.25) EPS for the quarter, hitting the consensus estimate of ($0.25). During the same quarter in the previous year, the company earned ($0.26) earnings per share. Analysts expect that Viking Therapeutics, Inc. will post -1.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Greg Zante sold 15,000 shares of Viking Therapeutics stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $17.90, for a total value of $268,500.00. Following the transaction, the chief financial officer now directly owns 180,730 shares of the company’s stock, valued at $3,235,067. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Sarah Kathryn Rouan sold 30,000 shares of Viking Therapeutics stock in a transaction on Friday, January 19th. The shares were sold at an average price of $23.05, for a total value of $691,500.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Greg Zante sold 15,000 shares of Viking Therapeutics stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $17.90, for a total transaction of $268,500.00. Following the completion of the transaction, the chief financial officer now directly owns 180,730 shares in the company, valued at $3,235,067. The disclosure for this sale can be found here. Insiders have sold a total of 374,079 shares of company stock valued at $9,729,653 over the last three months. 4.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Retirement Group LLC increased its position in Viking Therapeutics by 75.0% during the 2nd quarter. Retirement Group LLC now owns 2,100 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 900 shares during the period. Cetera Advisor Networks LLC purchased a new position in Viking Therapeutics during the 2nd quarter valued at $36,000. Wetzel Investment Advisors Inc. bought a new stake in shares of Viking Therapeutics during the 4th quarter valued at $37,000. Engineers Gate Manager LP bought a new stake in shares of Viking Therapeutics during the 1st quarter valued at $37,000. Finally, US Bancorp DE boosted its holdings in shares of Viking Therapeutics by 66.5% during the 4th quarter. US Bancorp DE now owns 2,346 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 937 shares in the last quarter. 78.13% of the stock is owned by hedge funds and other institutional investors.

Viking Therapeutics Company Profile

(Get Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

See Also

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.